IRIS
MARTINELLI, Erika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.361
NA - Nord America 6.182
AS - Asia 5.261
SA - Sud America 803
Continente sconosciuto - Info sul continente non disponibili 511
AF - Africa 69
OC - Oceania 19
Totale 25.206
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 8.155
US - Stati Uniti d'America 6.043
SG - Singapore 1.899
IE - Irlanda 1.252
CN - Cina 1.067
IT - Italia 842
HK - Hong Kong 832
BR - Brasile 654
VN - Vietnam 626
DE - Germania 466
GB - Regno Unito 438
UA - Ucraina 357
KR - Corea 299
FR - Francia 285
IN - India 146
FI - Finlandia 142
SE - Svezia 116
GR - Grecia 106
TR - Turchia 101
JP - Giappone 84
CA - Canada 81
AR - Argentina 56
BD - Bangladesh 44
NL - Olanda 43
AT - Austria 37
PK - Pakistan 36
MX - Messico 32
EC - Ecuador 30
IQ - Iraq 25
ID - Indonesia 24
PL - Polonia 22
BE - Belgio 21
ZA - Sudafrica 17
CZ - Repubblica Ceca 16
ES - Italia 16
MA - Marocco 14
CH - Svizzera 13
VE - Venezuela 13
AU - Australia 12
CO - Colombia 11
CL - Cile 9
KE - Kenya 9
PY - Paraguay 9
BO - Bolivia 8
PE - Perù 8
IR - Iran 7
NZ - Nuova Zelanda 7
PH - Filippine 7
SA - Arabia Saudita 7
TN - Tunisia 7
AZ - Azerbaigian 6
KG - Kirghizistan 6
LT - Lituania 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
IL - Israele 5
JM - Giamaica 5
JO - Giordania 5
GT - Guatemala 4
HN - Honduras 4
HU - Ungheria 4
NP - Nepal 4
SN - Senegal 4
UY - Uruguay 4
CR - Costa Rica 3
DO - Repubblica Dominicana 3
EG - Egitto 3
MK - Macedonia 3
RO - Romania 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
AL - Albania 2
BG - Bulgaria 2
BY - Bielorussia 2
ET - Etiopia 2
EU - Europa 2
GA - Gabon 2
GI - Gibilterra 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MY - Malesia 2
OM - Oman 2
RS - Serbia 2
TW - Taiwan 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
CG - Congo 1
CI - Costa d'Avorio 1
EE - Estonia 1
GE - Georgia 1
GH - Ghana 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
Totale 24.686
Salva come PNG Salva come JPEG
Città #
Moscow 2.983
Dublin 1.237
San Jose 867
Hong Kong 817
Singapore 803
Santa Clara 724
Chandler 607
Jacksonville 583
Ashburn 312
Seoul 274
Ho Chi Minh City 204
Beijing 194
Princeton 172
New York 158
Bremen 145
Council Bluffs 145
Naples 143
Roxbury 142
Hanoi 141
Dallas 133
Medford 131
Hefei 128
Ann Arbor 106
Munich 105
Los Angeles 100
The Dalles 84
Bengaluru 78
Wilmington 78
Caserta 76
São Paulo 71
Boardman 54
Cambridge 45
Des Moines 43
Chicago 41
San Mateo 41
Nanjing 39
Da Nang 36
Woodbridge 36
Haiphong 35
Napoli 32
Turku 32
Nuremberg 30
Orem 23
Amsterdam 22
Elora 22
Falkenstein 22
Vienna 22
Atlanta 21
Brussels 21
Rio de Janeiro 21
Shanghai 21
Tianjin 21
Tokyo 21
Brasília 20
Dong Ket 20
Houston 20
Norwalk 20
Frankfurt am Main 19
Helsinki 19
Milan 18
Warsaw 18
Brooklyn 17
Mountain View 17
Hải Dương 16
Montreal 16
Rome 16
Aversa 15
Guangzhou 14
Nanchang 14
Belo Horizonte 13
Brno 13
Columbus 13
Curitiba 13
Quito 13
Düsseldorf 12
London 12
Chennai 11
Istanbul 11
Jakarta 11
Manchester 11
Memphis 11
San Francisco 11
Changsha 10
Lappeenranta 10
Ninh Bình 10
Piscataway 10
Redwood City 10
Toronto 10
Auburn Hills 9
Giugliano in Campania 9
Guayaquil 9
Hangzhou 9
Hillsboro 9
Jinan 9
Mumbai 9
Bahawalpur 8
Biên Hòa 8
Chengdu 8
Ercolano 8
Guarulhos 8
Totale 13.039
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 253
Beyond N staging in colorectal cancer: Current approaches and future perspectives 226
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 211
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 209
ONCOLOGIA MEDICA 209
AXL is an oncotarget in human colorectal cancer 197
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 193
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 189
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 187
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 186
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 185
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 184
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 181
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 179
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 178
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 176
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry 176
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 168
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 166
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 164
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 164
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 164
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 164
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 164
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 163
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 163
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 162
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 162
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 161
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 160
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 160
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 155
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 154
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 154
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 152
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 152
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 151
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 150
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 148
The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria 148
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 148
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 147
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 147
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 147
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 147
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 146
Pimasertib hydrochloride 146
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 145
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 144
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 143
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 142
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 141
Farmacogenomica e cancro colorettale 139
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 139
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 137
Light alcohol drinking and the risk of cancer development: a controversial relationship 137
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 136
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 136
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 136
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ 136
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 134
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 134
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 133
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 133
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 133
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 132
Endoscopic calcium electroporation for unfit-for-surgery bleeding colorectal cancer: the dawn of a new treatment? 132
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study 131
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 130
TRASTUZUMAB RESISTANCE IN BREAST CANCER 130
EGFR in Tumor-associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. 130
Identification of perineural invasion at imaging staging as a novel potential risk factor in rectal cancer: A case report 129
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 129
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 129
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 128
[Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)] 128
Immunotherapy in advanced anal cancer: Is the beginning of a new era? 127
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 126
Chemoradiotherapy as adjuvant treatment of gastric cancer 126
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 126
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 126
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 125
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 125
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 125
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator 124
Targeting EGFR in Pancreatic Cancer Treatment. 124
Prevention of cardiovascular complications in elderly cancer patients 123
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 123
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 122
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 122
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 122
Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. 121
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 121
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 121
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 120
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors. A phase I study 120
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 120
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. 120
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 119
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 119
Totale 14.849
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.969
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.969
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.097 0 17 23 23 340 20 42 35 54 99 106 338
2022/20232.473 251 50 34 212 291 208 7 151 1.149 17 57 46
2023/2024992 93 37 38 51 335 140 19 24 11 14 74 156
2024/20253.318 56 105 54 107 471 432 339 320 471 448 268 247
2025/202614.012 559 606 669 682 1.097 7.587 705 749 606 374 238 140
2026/2027470 137 333 0 0 0 0 0 0 0 0 0 0
Totale 25.206